{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:08:26Z","timestamp":1783573706950,"version":"3.55.0"},"reference-count":12,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2003,5,19]],"date-time":"2003-05-19T00:00:00Z","timestamp":1053302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2003,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The authors conducted a 2\u2010arm Phase II trial of 9\u2010nitrocamptothecin (9\u2010NC), an oral topoisomerase I inhibitor, to define response rates in patients with gastrointestinal (GI) leiomyosarcomas and other soft\u2010tissue sarcomas (STS).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients were required to provide informed consent and have measurable disease, Zubrod performance status \u2264 2, and adequate organ function. 9\u2010NC was administered orally at 1.5 mg\/m<jats:sup>2<\/jats:sup> per day \u00d7 5 days every week. Response evaluation was performed at 8 weeks, and those with stable or responding disease continued treatment until maximal response was achieved. A total of 56 patients (30 females and 26 males) with a median age of 55 years (range, 19\u201379 years) were enrolled on the study. Seventeen patients were enrolled on the GI leiomyosarcoma arm; only 1 minor response, lasting &lt; 8 weeks in a patient with liver metastases, was noted, and so this arm was terminated. Thirty\u2010nine patients were entered on the other STS arm.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Three patients achieved a partial response (response rate, 8%) for durations of 4, 6, and 13 months, respectively. Fourteen patients had stable disease for a median of 4 months (range, 2\u20138 months). Two patients died of disease during the first 2 months. Four other patients required hospitalization for nausea, vomiting, and dehydration. Other toxicities included diarrhea (36 patients, 5 with Grade 3 toxicity); fatigue (42 patients, 11 with Grade 3 toxicity); anorexia (32 patients, 1 with Grade 3 toxicity); nausea (37 patients, 2 with Grade 3 toxicity); vomiting (24 patients, 3 with Grade 3 toxicity); neutropenia (14 patients, 5 with Grade 3 toxicity); and thrombocytopenia (16 patients, 5 with Grade 3 or 4 toxicity).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>9\u2010NC is well tolerated but inactive in GI leiomyosarcomas and has minimal activity in previously treated patients with STS. Cancer 2003;97:2848\u201352. \u00a9 2003 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.11385<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.11385","type":"journal-article","created":{"date-parts":[[2003,5,21]],"date-time":"2003-05-21T06:01:27Z","timestamp":1053496887000},"page":"2848-2852","source":"Crossref","is-referenced-by-count":26,"title":["Results of a 2\u2010arm Phase II study of 9\u2010nitrocamptothecin in patients with advanced soft\u2010tissue sarcomas"],"prefix":"10.1002","volume":"97","author":[{"given":"Shreyaskumar R.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Beach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Andrew","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Trent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,5,19]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.52.1.23"},{"key":"e_1_2_5_3_2","first-page":"352","article-title":"Evaluation of ifosfamide in metastatic leiomyosarcomas of GI origin","volume":"31","author":"Patel SR","year":"1991","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_5_4_2","first-page":"325","article-title":"Differential responsiveness of leiomyosarcoma (leio) arising at different sites to doxorubicin\u2010based chemotherapy","volume":"38","author":"Patel SR","year":"1997","journal-title":"Proc Am Assoc Cancer Res."},{"key":"e_1_2_5_5_2","first-page":"453","volume-title":"American Society of Clinical Oncology educational booklet (Spring 2000)","author":"Patel SR","year":"2000"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.7.1545"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00968a057"},{"key":"e_1_2_5_8_2","first-page":"5077","article-title":"Arrest of replication forks by drug stabilized topoisomerase I\u2010DNA cleavable complexes as a mechanism of cell killing by camptothecin","volume":"49","author":"Hsiang Y\u2010H","year":"1989","journal-title":"Cancer Res."},{"key":"e_1_2_5_9_2","first-page":"6636","article-title":"Camptothecin and its derivatives induce expression of the c\u2010jun proto\u2010oncogene in human myeloid leukemia cells","volume":"51","author":"Kharbanda S","year":"1991","journal-title":"Cancer Res."},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1996.tb26392.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.15.3463"},{"key":"e_1_2_5_13_2","first-page":"407a","article-title":"Response of chordoma to a protracted schedule of 9\u2010NC: an update","volume":"21","author":"Mace JR","year":"2002","journal-title":"Proc Am Soc Clin Oncol."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.11385","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.11385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:45:56Z","timestamp":1760258756000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.11385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,19]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["10.1002\/cncr.11385"],"URL":"https:\/\/doi.org\/10.1002\/cncr.11385","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,19]]}}}